2022
Clinical and Financial Outcomes Associated With a Workplace Mental Health Program Before and During the COVID-19 Pandemic
Bondar J, Morrow C, Gueorguieva R, Brown M, Hawrilenko M, Krystal JH, Corlett PR, Chekroud AM. Clinical and Financial Outcomes Associated With a Workplace Mental Health Program Before and During the COVID-19 Pandemic. JAMA Network Open 2022, 5: e2216349. PMID: 35679044, PMCID: PMC9185188, DOI: 10.1001/jamanetworkopen.2022.16349.Peer-Reviewed Original ResearchConceptsMental health programsHealth programsCohort studyLarge clinical effect sizesPatient Health Questionnaire-9Common mental health conditionsSheehan Disability ScaleClinical effect sizeMental health conditionsMental health symptomsCost of treatmentGeneralized anxiety disorderMental health difficultiesMental health benefitsWorkplace wellness programsCare navigationClinical improvementPrimary outcomeClinical benefitQuestionnaire-9Disability ScaleMedication managementLeast moderate anxietyMixed-effects regressionPerson psychotherapy
2020
Convergent molecular, cellular, and cortical neuroimaging signatures of major depressive disorder
Anderson KM, Collins MA, Kong R, Fang K, Li J, He T, Chekroud AM, Yeo BTT, Holmes AJ. Convergent molecular, cellular, and cortical neuroimaging signatures of major depressive disorder. Proceedings Of The National Academy Of Sciences Of The United States Of America 2020, 117: 25138-25149. PMID: 32958675, PMCID: PMC7547155, DOI: 10.1073/pnas.2008004117.Peer-Reviewed Original ResearchMeSH KeywordsAstrocytesAutopsyBrainCerebral CortexDepressive Disorder, MajorFemaleGene Expression ProfilingGene Expression RegulationGene OntologyGene Regulatory NetworksGenome-Wide Association StudyGenomicsHumansInterneuronsMaleMultifactorial InheritanceNeuroimagingSignal TransductionSingle-Cell AnalysisSomatostatinConceptsGenome-wide association studiesTranscriptional dataTranscriptional correlatesMajor depressive disorderCorrelates of depressionGene transcriptionSpecific genesGene expressionGene dysregulationIntegrative analysisBiological pathwaysAssociation studiesExpression dataGenesMolecular pathwaysCortical gene expressionDepressive disorderEx vivo geneCells associatesIntegrated analysisVivo geneBiological systemsRegulationPathwayUK BiobankSymptom clusters in adolescent depression and differential response to treatment: a secondary analysis of the Treatment for Adolescents with Depression Study randomised trial
Bondar J, Caye A, Chekroud A, Kieling C. Symptom clusters in adolescent depression and differential response to treatment: a secondary analysis of the Treatment for Adolescents with Depression Study randomised trial. The Lancet Psychiatry 2020, 7: 337-343. PMID: 32199509, DOI: 10.1016/s2215-0366(20)30060-2.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentBayes TheoremChildCognitive Behavioral TherapyCombined Modality TherapyDepressive Disorder, MajorDiagnostic and Statistical Manual of Mental DisordersFemaleFluoxetineHumansMalePsychiatric Status Rating ScalesSelective Serotonin Reuptake InhibitorsTreatment OutcomeUnited StatesConceptsChildren's Depression Rating Scale-RevisedCognitive behavioral therapyCDRS-R scoresSymptom clustersDepression StudyTreatment efficacySecondary analysisMajor depressive disorderDSM-IV diagnosisCo-occurring symptomsSpecific symptom clustersPlacebo groupAcute phaseClinical profileActive treatmentSymptom scoresSleep disturbancesClinical trialsDepressive disorderPill placeboTreatment responseTherapeutic modalitiesSpecific symptomsNew therapiesPhysical complaints
2019
Altered functional connectivity and low-frequency signal fluctuations in early psychosis and genetic high risk
Tang Y, Zhou Q, Chang M, Chekroud A, Gueorguieva R, Jiang X, Zhou Y, He G, Rowland M, Wang D, Fu S, Yin Z, Leng H, Wei S, Xu K, Wang F, Krystal JH, Driesen NR. Altered functional connectivity and low-frequency signal fluctuations in early psychosis and genetic high risk. Schizophrenia Research 2019, 210: 172-179. PMID: 30685394, DOI: 10.1016/j.schres.2018.12.041.Peer-Reviewed Original ResearchConceptsFunctional connectivityHigh-risk individualsAltered functional connectivityHealthy comparison subjectsGenetic high riskGenetic high-risk individualsLow-frequency signal fluctuationsFunctional magnetic resonanceALFF abnormalitiesALFF measuresFunctional connectivity measuresBasal gangliaFirst episodeHigh riskEarly psychosisComparison subjectsSchizophrenia diathesisSchizophrenia vulnerabilityFESzGenetic riskLow-frequency fluctuationsIllnessSchizophreniaVoxel connectivityGHR
2018
Reading the (functional) writing on the (structural) wall: Multimodal fusion of brain structure and function via a deep neural network based translation approach reveals novel impairments in schizophrenia
Plis SM, Amin MF, Chekroud A, Hjelm D, Damaraju E, Lee HJ, Bustillo JR, Cho K, Pearlson GD, Calhoun VD. Reading the (functional) writing on the (structural) wall: Multimodal fusion of brain structure and function via a deep neural network based translation approach reveals novel impairments in schizophrenia. NeuroImage 2018, 181: 734-747. PMID: 30055372, PMCID: PMC6321628, DOI: 10.1016/j.neuroimage.2018.07.047.Peer-Reviewed Original ResearchConceptsGray matter patternsIntrinsic connectivity networksPosterior cingulate cortexHealthy controlsDynamic functional connectivityStructural MRIFunctional MRIDFNC statesGray matter densitySignificant group differencesTemporal lobeTemporal cortexCingulate cortexSame brainFunctional connectivityBrain structuresCognitive scoresStrong associationLinkage/associationMultimodal brain imaging dataImaging dataGroup differencesSignificant correlationSMRI dataCortexMultivariate Pattern Analysis of Genotype–Phenotype Relationships in Schizophrenia
Zheutlin AB, Chekroud AM, Polimanti R, Gelernter J, Sabb FW, Bilder RM, Freimer N, London ED, Hultman CM, Cannon TD. Multivariate Pattern Analysis of Genotype–Phenotype Relationships in Schizophrenia. Schizophrenia Bulletin 2018, 44: 1045-1052. PMID: 29534239, PMCID: PMC6101611, DOI: 10.1093/schbul/sby005.Peer-Reviewed Original ResearchConceptsMultivariate pattern analysisIndependent samplesVisual memoryCognitive endophenotypesPredictive strengthSchizophreniaMemoryIndividual variationPattern analysisSingle predictorCertain domainsDiscovery samplePsychiatric patientsPolygenic risk scoresPredictive powerScoresEndophenotypesPotential relationshipRelationshipRandom forestGenetic risk variantsLimited setPredictorsComprehensive setSamples
2017
Differences in words used to describe racial and gender groups in Medical Student Performance Evaluations
Ross DA, Boatright D, Nunez-Smith M, Jordan A, Chekroud A, Moore EZ. Differences in words used to describe racial and gender groups in Medical Student Performance Evaluations. PLOS ONE 2017, 12: e0181659. PMID: 28792940, PMCID: PMC5549898, DOI: 10.1371/journal.pone.0181659.Peer-Reviewed Original ResearchReevaluating the Efficacy and Predictability of Antidepressant Treatments: A Symptom Clustering Approach
Chekroud AM, Gueorguieva R, Krumholz HM, Trivedi MH, Krystal JH, McCarthy G. Reevaluating the Efficacy and Predictability of Antidepressant Treatments: A Symptom Clustering Approach. JAMA Psychiatry 2017, 74: 370-378. PMID: 28241180, PMCID: PMC5863470, DOI: 10.1001/jamapsychiatry.2017.0025.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAffectAgedAntidepressive AgentsBupropionCitalopramCluster AnalysisDepressive Disorder, MajorDose-Response Relationship, DrugDrug Therapy, CombinationDuloxetine HydrochlorideFemaleHumansMaleMianserinMiddle AgedMirtazapineRandomized Controlled Trials as TopicSleepSyndromeTreatment OutcomeVenlafaxine HydrochlorideYoung AdultConceptsCore emotional symptomsDepressive severitySymptom clustersHamilton Depression Rating ScaleDepression Outcomes trialDifferent antidepressant medicationsHAM-D scaleHigh-dose duloxetinePhase 3 trialEmotional symptomsPatient-reported dataDepression Rating ScaleSequenced Treatment AlternativesGroup of symptomsCluster of symptomsDepressive symptom checklistMixed-effects regression analysisDepressive Symptomatology ScaleAntidepressant therapyAntidepressant treatmentAntidepressant medicationOutcome trialsCombining MedicationsAtypical symptomsAdditional placeboThe Role of microRNA Expression in Cortical Development During Conversion to Psychosis
Zheutlin AB, Jeffries CD, Perkins DO, Chung Y, Chekroud AM, Addington J, Bearden CE, Cadenhead KS, Cornblatt BA, Mathalon DH, McGlashan TH, Seidman LJ, Walker EF, Woods SW, Tsuang M, Cannon TD. The Role of microRNA Expression in Cortical Development During Conversion to Psychosis. Neuropsychopharmacology 2017, 42: 2188-2195. PMID: 28186095, PMCID: PMC5603810, DOI: 10.1038/npp.2017.34.Peer-Reviewed Original ResearchConceptsNorth American Prodrome Longitudinal StudyCortical thinningDisease onsetClinical high-risk individualsProinflammatory cytokine levelsHigh-risk individualsGray matter reductionsOnset of psychosisCortical gray matter reductionMicroRNA expressionMicroglial actionCytokine levelsProinflammatory cytokinesCortical maturationImmune cellsHealthy controlsInflammatory responsePeripheral leukocytesCortical developmentHigh riskImmune functionSynaptic plasticityImmune systemConversion statusResident macrophagesTrajectories of relapse in randomised, placebo-controlled trials of treatment discontinuation in major depressive disorder: an individual patient-level data meta-analysis
Gueorguieva R, Chekroud AM, Krystal JH. Trajectories of relapse in randomised, placebo-controlled trials of treatment discontinuation in major depressive disorder: an individual patient-level data meta-analysis. The Lancet Psychiatry 2017, 4: 230-237. PMID: 28189575, PMCID: PMC5340978, DOI: 10.1016/s2215-0366(17)30038-x.Peer-Reviewed Original ResearchConceptsActive medicationActive treatmentClinical trialsDepression severityHamilton Depression Rating Scale scoresDepression Rating Scale scoresClinical Global Impression scoresIndividual patient-level dataDouble-blind treatmentPlacebo-controlled trialPatterns of relapseGlobal Impression scoresIndividual patient dataPrevention of relapseTrajectory class membershipTreatment of depressionMajor depressive disorderRating Scale scoresPatient-level dataPost-traumatic stress disorderTreatment discontinuationAntidepressant treatmentClinical responseAlcohol Research CenterAntidepressant medication
2016
Altered functional brain connectivity in children and young people with opsoclonus–myoclonus syndrome
Chekroud A, Anand G, Yong J, Pike M, Bridge H. Altered functional brain connectivity in children and young people with opsoclonus–myoclonus syndrome. Developmental Medicine & Child Neurology 2016, 59: 98-104. PMID: 27658927, DOI: 10.1111/dmcn.13262.Peer-Reviewed Original ResearchConceptsOpsoclonus-myoclonus syndromeMagnetic resonance imagingMotor cortexOccipito-parietal regionsAltered functional brain connectivityWidespread brain involvementResting-state functional MRI dataComparison groupStructural brain changesCross-sectional studyFunctional brain connectivitySeed-based analysisBrain functional connectivityAge-matched comparison participantsBrain involvementMotor sequelaeBasal gangliaBrain changesPatientsResonance imagingBrain regionsFunctional MRI dataFunctional connectivityVisual networkBrain connectivityMultisite prediction of 4-week and 52-week treatment outcomes in patients with first-episode psychosis: a machine learning approach
Koutsouleris N, Kahn R, Chekroud A, Leucht S, Falkai P, Wobrock T, Derks E, Fleischhacker W, Hasan A. Multisite prediction of 4-week and 52-week treatment outcomes in patients with first-episode psychosis: a machine learning approach. The Lancet Psychiatry 2016, 3: 935-946. PMID: 27569526, DOI: 10.1016/s2215-0366(16)30171-7.Peer-Reviewed Original ResearchConceptsFirst-episode psychosisTreatment outcomesEuropean First Episode Schizophrenia TrialKaplan-Meier log-rank analysisLog-rank analysisReal-world careWeeks of treatmentPrevious depressive episodesCommencement of treatmentPoor treatment outcomesFirst-episode sampleBetter treatment outcomesClinical trial designQuality of lifeMeaningful outcome indicatorsHospital eventsMale sexOutcome predictorsDepressive episodeTreatment adherenceFunctional deficitsSchizophrenia trialsSuperior efficacyNew patientsSymptom persistence
2014
Cerebellar and cortical abnormalities in paediatric opsoclonus‐myoclonus syndrome
Anand G, Bridge H, Rackstraw P, Chekroud A, Yong J, Stagg C, Pike M. Cerebellar and cortical abnormalities in paediatric opsoclonus‐myoclonus syndrome. Developmental Medicine & Child Neurology 2014, 57: 265-272. PMID: 25290446, DOI: 10.1111/dmcn.12594.Peer-Reviewed Original ResearchConceptsOpsoclonus-myoclonus syndromePediatric opsoclonus-myoclonus syndromeGray matter volumeCortical thicknessDiffusion-weighted imagesCerebellar atrophyFlocculonodular lobeMatter volumeMagnetic resonance spectroscopy scansCerebral cortical thicknessTract-based spatial statisticsT1-weighted structural imagesCerebellar gray matter volumeWhole-brain levelWhole-brain analysisWhite matter integrityCerebellar gray matterPersistent symptomatologyClinical outcomesMotor sequelaeChronic phaseCortical abnormalitiesMotor cortexBrain levelsOMS group